Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Κύριος συγγραφέας: | Leng, H |
---|---|
Άλλοι συγγραφείς: | Simon, K |
Μορφή: | Thesis |
Γλώσσα: | English |
Έκδοση: |
2019
|
Θέματα: |
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
ανά: Mabilleau, G, κ.ά.
Έκδοση: (2009) -
Stimulation of osteoclast formation by inflammatory synovial fluid
ανά: Adamopoulos, I, κ.ά.
Έκδοση: (2006) -
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
ανά: Mabilleau, G, κ.ά.
Έκδοση: (2008) -
Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease
ανά: Magetsari, Rahadyan, κ.ά.
Έκδοση: (2022) -
Maintenance therapy in multiple myeloma
ανά: Jean-Luc Harousseau
Έκδοση: (2009-08-01)